Celltrion Obtains Domestic Approval for Product Modification of COVID-19 Treatment 'Rekkirona J'
[Asia Economy Reporter Oh Hyung-gil] Celltrion announced on the 17th that it has obtained domestic product modification approval for the COVID-19 virus (SARS-CoV-2) treatment 'Rekkironaju (CT-P59)' from the Ministry of Food and Drug Safety.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051414165763158_1778735817.jpg)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
- [Breaking] Park Sukeun, Central Labor Relations Commission Chair: "Some Gaps Narrowed Between Samsung Electronics Labor and Management"
- "I Take Full Responsibility"... Chung Yongjin Issues Direct Apology for Starbucks 'May 18 Controversy' (Update)
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
The company stated, "In the situation where confirmed cases are increasing due to the prolonged COVID-19 pandemic, demand for treatments is expected to remain steady. It can contribute to normalizing the COVID-19 situation by reducing the rate at which existing patients' symptoms worsen to severe conditions or death." They added, "We plan to apply for emergency use authorization and approval in each country through continuous discussions with global regulatory agencies."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
